Unlike PAR1 agonist treatment, the ratio of CD62P+/CD62P− platelets remained unchanged between CA9-treated and untreated BC-derived platelets, indicating that soluble CA9 (sCA9) is unable to activate platelets (Figure S5B). Here, CA9 is linked to breast cancer.